Repligen Corp. is a global life sciences company, which engages in providing bioprocessing technologies and solutions used in the process of manufacturing biological drugs. It operates through the ...

I reiterate a 'buy' rating for Repligen with a one-year price target of $175 per share, driven by strong bioprocessing market recovery. Repligen reported 3% organic revenue growth and 13% growth ...

Biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) in Q4 CY2024, but sales were flat year on year at $167.5 million. The company’s outlook for the full year was close to analysts ...

Repligen (NASDAQ:RGEN), a bioprocessing technology company, announced its earnings for the fourth quarter on Feb. 20. Its adjusted earnings per share (EPS) of $0.44 exceeded analysts' consensus ...

Repligen Corporation RGEN reported fourth-quarter 2024 adjusted earnings per share of 44 cents, which beat the Zacks Consensus Estimate of 41 cents. The company had recorded adjusted earnings of ...

(RTTNews) - Repligen Corporation (RGEN), a life sciences company, Thursday reported net loss of $33.87 million or $0.60 per share for the fourth quarter, wider than $16.45 million or $0.29 per ...

Repligen has a 52 week low of $113.50 and a 52 week high of $203.13. The firm has a market capitalization of $8.91 billion, a P/E ratio of -311.75, a P/E/G ratio of 4.54 and a beta of 0.99.

WALTHAM, Mass., & BOSTON, March 04, 2025--(BUSINESS WIRE)--Repligen Corporation (Nasdaq: RGEN), a life sciences company focused on bioprocessing technology leadership, and 908 Devices Inc. (Nasdaq ...

We recently published a list of Top 10 Stocks to Buy According to 12 West Capital Management. In this article, we are going to take a look at where Repligen Corporation (NASDAQ:RGEN) stands against ...